Breaking News Instant updates and real-time market news.

RXDX

Ignyta

$6.25

-0.1 (-1.57%)

07:55
12/01/16
12/01
07:55
12/01/16
07:55

Ignyta to hold a conference call

In conjunction with the Company's presentations at the 2016 EORTC-NCI-AACR Symposium, management provides a substantial Phase 1b clinical data update of RXDX-105, as well as RXDX-106, on a conference call to be held on December 1 at 8 am. Webcast Link

  • 01

    Dec

RXDX Ignyta
$6.25

-0.1 (-1.57%)

04/18/16
PIPR
04/18/16
NO CHANGE
Target $32
PIPR
Overweight
Ignyta remains a top pick at Piper Jaffray
Piper Jaffray analyst Joshua Schimmer says Ignyta (RXDX) remains a top pick after the company over the weekend reported additional data from the ongoing entrectinib Phase 1 ALKA and STARTRK studies. The data continue to highlight the clinical activity in solid tumors as well as a generally tolerable profile, Schimmer tells investors in a research note. Loxo Oncology (LOXO) also reported Phase 1 data for an NTRK inhibitor, and the two drugs "appear fairly similar," the analyst contends. Schimmer believes this should help drive positive sentiment for Ignyta since there was investor concern that the Loxo data would appear superior. He keeps an Overweight rating on Ignyta with a $32 price target.
04/18/16
LEER
04/18/16
NO CHANGE
LEER
Outperform
Ignyta entrectinib continues to show 'encouraging' efficacy, says Leerink
Leerink analyst Paul Matteis says Ignyta's (RXDX) entrectinib continues to show "encouraging" efficacy and safety in an expanding sample of treated patients, following updated Phase 1 data presented by the company. The analyst says entrectinib shows "strong efficacy" in ROS1 with an 86% response rate, an 85% response rate in non-small cell lung cancer and multiple responses past 18 months. Loxo Oncology's (LOXO) LOXO-101, a competing inhibitor, also showed "nice efficacy data" with a comparable response rate, Matteis tells investors in a research note. The analyst reiterates an Outperform rating on Ignyta's shares.
05/11/16
PIPR
05/11/16
NO CHANGE
Target $32
PIPR
Overweight
Piper still surprised by Ignyta's 'modest valuation'
Piper Jaffray analyst Joshua Schimmer says he remains surprised by Ignyta's "modest valuation" given the company's "multiple attractive assets." Ignyta reported Q1 results last night provided some useful updates on entrectinib and taladegib, Schimmer tells investors in a research note. He keeps an Overweight rating on the shares with a $32 price target.
06/23/16
JPMS
06/23/16
INITIATION
Target $15
JPMS
Overweight
Ignyta initiated with an Overweight at JPMorgan
JPMorgan analyst Anupam Rama started Ignyta with an Overweight rating and $15 price target, saying the company's lead program entrectinib is underappreciated from both a clinical and commercial perspective. Rama also views taladegib and RXDX-105 as interesting assets and potential long-term value drivers, though they are not currently included in the valuation model used to arrive at the $15 target.

TODAY'S FREE FLY STORIES

INVH

Invitation Homes

$21.56

0.12 (0.56%)

15:06
06/23/17
06/23
15:06
06/23/17
15:06
Upgrade
Invitation Homes rating change  »

Invitation Homes upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:05
06/23/17
06/23
15:05
06/23/17
15:05
General news
NY Fed's 3-day reverse repo totaled $201.5 B with 56 counterparties »

NY Fed's 3-day…

DAL

Delta Air Lines

$52.95

0.14 (0.27%)

15:03
06/23/17
06/23
15:03
06/23/17
15:03
Hot Stocks
Delta Air Lines, Korean Air create leading trans-Pacific joint venture »

Delta Air Lines and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 30

    Jun

  • 07

    Jul

XLV

Health Care Select Sector SPDR

$80.33

-0.26 (-0.32%)

, XLK

Technology Select Sector SPDR

$56.28

0.33 (0.59%)

14:59
06/23/17
06/23
14:59
06/23/17
14:59
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

The S&P 500 (SPX) at…

XLV

Health Care Select Sector SPDR

$80.33

-0.26 (-0.32%)

XLK

Technology Select Sector SPDR

$56.28

0.33 (0.59%)

XLF

Financial Select Sector

$23.91

-0.07 (-0.29%)

XLE

Energy Select Sector SPDR

$64.16

0.21 (0.33%)

SPY

SPDR S&P 500 ETF Trust

$243.10

0.26 (0.11%)

SPX

S&P 500

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSN

Tyson Foods

$62.64

0.918 (1.49%)

14:57
06/23/17
06/23
14:57
06/23/17
14:57
Periodicals
Breaking Periodicals news story on Tyson Foods »

Hedgeye names Tyson Foods…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PAA

Plains All American

$24.53

0.6301 (2.64%)

14:50
06/23/17
06/23
14:50
06/23/17
14:50
Options
Bullish long-term option play opened in Plains All American Pipeline »

Bullish long-term option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 08

    Nov

LION

Fidelity Southern

$22.59

0.01 (0.04%)

14:46
06/23/17
06/23
14:46
06/23/17
14:46
Hot Stocks
Fidelity Southern announces appointment of Charles Christy as CFO »

Fidelity Southern…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

14:40
06/23/17
06/23
14:40
06/23/17
14:40
General news
Fedspeak will resume with Chair Yellen »

Fedspeak will resume with…

14:30
06/23/17
06/23
14:30
06/23/17
14:30
Options
Alerian MLP attracts call buyers as shares attempt to rebound »

Alerian MLP attracts call…

LITE

Lumentum

$62.45

-0.05 (-0.08%)

14:25
06/23/17
06/23
14:25
06/23/17
14:25
Options
Lumentum call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 12

    Jul

  • 13

    Jul

14:20
06/23/17
06/23
14:20
06/23/17
14:20
General news
Action Economics Survey results »

Action Economics Survey…

NTDOY

Nintendo

$42.05

0.435 (1.05%)

, SNE

Sony

$38.52

0.11 (0.29%)

14:17
06/23/17
06/23
14:17
06/23/17
14:17
Periodicals
Nintendo market cap surpasses Sony's in Japan, Nikkei reports »

Nintendo's (NTDOY)…

NTDOY

Nintendo

$42.05

0.435 (1.05%)

SNE

Sony

$38.52

0.11 (0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

14:17
06/23/17
06/23
14:17
06/23/17
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

14:16
06/23/17
06/23
14:16
06/23/17
14:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

14:15
06/23/17
06/23
14:15
06/23/17
14:15
Conference/Events
Portola Pharmaceuticals hold a conference call »

Management holds a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

SAFM

Sanderson Farms

$123.21

-2.89 (-2.29%)

14:08
06/23/17
06/23
14:08
06/23/17
14:08
Hot Stocks
Sanderson Farms to 'vigorously defend' California chicken lawsuit »

Sanderson Farms issued a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

RH

$60.50

3.847 (6.79%)

14:05
06/23/17
06/23
14:05
06/23/17
14:05
Options
Restoration Hardware call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:00
06/23/17
06/23
14:00
06/23/17
14:00
General news
Breaking General news story  »

Federal Reserve Board…

BLCM

Bellicum Pharmaceuticals

$13.98

1.33 (10.51%)

13:51
06/23/17
06/23
13:51
06/23/17
13:51
Recommendations
Bellicum Pharmaceuticals analyst commentary  »

Bellicum selloff after…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 26

    Sep

MDRX

Allscripts

$12.71

0.52 (4.27%)

13:50
06/23/17
06/23
13:50
06/23/17
13:50
Options
Second day of bullish option flow in Allscripts »

Second day of bullish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTNX

Nutanix

$18.50

0.16 (0.87%)

13:45
06/23/17
06/23
13:45
06/23/17
13:45
Options
Nutanix call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

13:40
06/23/17
06/23
13:40
06/23/17
13:40
General news
And now Fed's Mester warns that a failure to hike »

And now Fed's Mester…

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

13:36
06/23/17
06/23
13:36
06/23/17
13:36
Hot Stocks
Breaking Hot Stocks news story on Portola Pharmaceuticals »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

PTLA

Portola Pharmaceuticals

$38.25

-1.24 (-3.14%)

13:35
06/23/17
06/23
13:35
06/23/17
13:35
Hot Stocks
Breaking Hot Stocks news story on Portola Pharmaceuticals »

Portola Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jun

  • 24

    Jun

GE

General Electric

$27.59

0.035 (0.13%)

13:30
06/23/17
06/23
13:30
06/23/17
13:30
Options
19.1K GE Jul - Aug 29 call spreads sold at 12c »

19.1K GE Jul - Aug 29…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.